Novo Nordisk A/S (NVO)
123.05
-0.97
(-0.78%)
USD |
NYSE |
May 03, 16:00
123.01
-0.04
(-0.03%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (TTM): 4.992B for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.992B |
| December 31, 2023 | 4.708B |
| September 30, 2023 | 4.310B |
| June 30, 2023 | 3.886B |
| March 31, 2023 | 3.578B |
| December 31, 2022 | 3.393B |
| September 30, 2022 | 3.148B |
| June 30, 2022 | 3.059B |
| March 31, 2022 | 2.965B |
| December 31, 2021 | 2.819B |
| September 30, 2021 | 2.671B |
| June 30, 2021 | 2.611B |
| March 31, 2021 | 2.458B |
| December 31, 2020 | 2.376B |
| September 30, 2020 | 2.308B |
| June 30, 2020 | 2.230B |
| March 31, 2020 | 2.279B |
| December 31, 2019 | 2.129B |
| September 30, 2019 | 2.174B |
| June 30, 2019 | 2.206B |
| March 31, 2019 | 2.199B |
| December 31, 2018 | 2.339B |
| September 30, 2018 | 2.274B |
| June 30, 2018 | 2.232B |
| March 31, 2018 | 2.209B |
| Date | Value |
|---|---|
| December 31, 2017 | 2.132B |
| September 30, 2017 | 2.150B |
| June 30, 2017 | 2.143B |
| March 31, 2017 | 2.144B |
| December 31, 2016 | 2.161B |
| September 30, 2016 | 2.104B |
| June 30, 2016 | 2.076B |
| March 31, 2016 | 2.019B |
| December 31, 2015 | 2.023B |
| September 30, 2015 | 2.080B |
| June 30, 2015 | 2.240B |
| March 31, 2015 | 2.356B |
| December 31, 2014 | 2.445B |
| September 30, 2014 | 2.447B |
| June 30, 2014 | 2.294B |
| March 31, 2014 | 2.205B |
| December 31, 2013 | 2.093B |
| September 30, 2013 | 2.001B |
| June 30, 2013 | 1.943B |
| March 31, 2013 | 1.910B |
| December 31, 2012 | 1.882B |
| September 30, 2012 | 1.822B |
| June 30, 2012 | 1.812B |
| March 31, 2012 | 1.818B |
| December 31, 2011 | 1.796B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.129B
Minimum
Dec 2019
4.992B
Maximum
Mar 2024
3.015B
Average
2.745B
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.069B |
| Vertex Pharmaceuticals Inc | 3.163B |
| Viking Therapeutics Inc | 76.90M |
| Evaxion Biotech AS | 11.92M |
| Moderna Inc | 4.777B |